Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

NCT06923072 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

NIH

Sponsor class

Conditions

Kohlmeier-Degos Disease
Malignant Atrophic Papulosis
Degos Disease
Papulosis, Malignant Atrophic

Interventions

DRUG: Baricitinib

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)